Welch D R, Fabra A, Nakajima M
Division of Chemotherapy, Glaxo Research Laboratories, Research Triangle Park, NC 27709.
Proc Natl Acad Sci U S A. 1990 Oct;87(19):7678-82. doi: 10.1073/pnas.87.19.7678.
The experimental metastatic potential of 13762NF mammary adenocarcinoma clone MTLn3 was tested after pretreatment in serum-free medium containing transforming growth factor (TGF) beta 1 at 0-5000 pg/ml. Lung colonies were measured 2 weeks after inoculation in syngeneic F344 rats, and a bell-shaped dose-response curve with 2- to 3-fold increase in number of surface lung metastases was seen. Maximal enhancement occurred at the 50 pg/ml dose level. The effect was specific because addition of neutralizing anti-TGF-beta antibody blocked the stimulatory activity at all levels of TGF-beta 1 pretreatment, but when antibody was given alone, neutralizing anti-TGF-beta antibody had no effect on untreated cells. Increased metastatic potential appears to be from an increased propensity of cells to extravasate as tested in the membrane invasion culture system. MTLn3 cells penetrated reconstituted basement-membrane barriers 2- to 3.5-fold more than did untreated control cells, depending upon length of TGF-beta 1 exposure. Increased invasive potential is apparently due, in part, to a 2- to 6-fold increase in type IV collagenolytic (gelatinolytic) and a 2.4-fold increase in heparanase activity. TGF-beta 1 treatment of MTLn3 cells did not alter their growth rate or morphology in the presence of serum; however, growth was inhibited in serum-free medium. Likewise, adhesion to human umbilical vein endothelial cell monolayers or to immobilized reconstituted basement membrane or fibronectin matrices was unchanged. These results suggest that TGF-beta 1 may modulate metastatic potential of mammary tumor cells by controlling their ability to break down and penetrate basement-membrane barriers.
在含有0 - 5000 pg/ml转化生长因子(TGF)β1的无血清培养基中进行预处理后,测试了13762NF乳腺腺癌克隆MTLn3的实验性转移潜能。在同基因F344大鼠接种2周后测量肺集落,观察到呈钟形的剂量反应曲线,肺表面转移灶数量增加了2至3倍。最大增强作用出现在50 pg/ml剂量水平。该效应具有特异性,因为添加中和性抗TGF-β抗体可在所有TGF-β1预处理水平阻断刺激活性,但单独给予抗体时,中和性抗TGF-β抗体对未处理细胞无影响。如在膜侵袭培养系统中所测试的,转移潜能增加似乎源于细胞外渗倾向的增加。MTLn3细胞穿透重组基底膜屏障的能力比未处理的对照细胞高2至3.5倍,这取决于TGF-β1暴露的时长。侵袭潜能增加显然部分归因于IV型胶原酶(明胶酶)活性增加2至6倍以及乙酰肝素酶活性增加2.4倍。在有血清存在的情况下,TGF-β1处理MTLn3细胞并未改变其生长速率或形态;然而,在无血清培养基中生长受到抑制。同样,对人脐静脉内皮细胞单层、固定化重组基底膜或纤连蛋白基质的黏附也未改变。这些结果表明,TGF-β1可能通过控制乳腺肿瘤细胞分解和穿透基底膜屏障的能力来调节其转移潜能。